Adaptive Phage Therapeutics Announces Licensing Agreement with the Walter Reed Army Institute of Research

  01 September 2021

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that it has entered into a licensing agreement with The Walter Reed Army Institute of Research (WRAIR) to provide APT access to the Institute’s extensive phage database. The agreement with the United States Army is synergistic with APT’s ongoing partnership with the United States Navy, providing the company with access to the pre-eminent phage database of the United States military to treat critically ill patients.

Further reading: Pipeline Review
Author(s): Pipeline Review
Healthy Patients  
Back

OUR UNDERWRITERS

Unrestricted financial support kindly provided by

Antimicrobial Resistance Fighter Coalition

CDD VAULT Complexity Simplified





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!